BRIEF-Lilly says phase 3 breast cancer study meets primary endpoint By: Reuters: Company News March 20, 2017 at 07:03 AM EDT * Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival Read More >> Related Stocks: Eli Lilly